drugset / Trial / NCT01216046

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

NCT01216046

Phase 1 Completed 48 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the pharmacokinetics and safety of VX-809 and VX-770 alone and in combination in healthy subjects.

Timeline

Start
2010-10
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivacaftor Other / unclassified Oral
Subject Lumacaftor Small molecule Oral

Indications